Form 4: Cellectar Biosciences: CEO Granted Stock Options

Cellectar Biosciences, Inc. reports the grant of stock options to President & CEO James V. Caruso, contingent on stockholder approval.

Summary

• James V. Caruso, President & CEO and Director of Cellectar Biosciences, Inc., was granted stock options on July 7, 2026.
• The grant consists of options to purchase 250,000 shares of common stock at an exercise price of $3.14 per share.
• The options were contingently granted on May 28, 2026, and became effective upon stockholder approval of the amended 2021 Stock Incentive Plan at the 2026 Annual Meeting of Stockholders on July 7, 2026.
• The options will vest over a three-year period starting from May 28, 2026, with one-third vesting on the first anniversary and the remainder vesting in equal monthly installments over the subsequent 24 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard executive compensation event (stock option grant) rather than significant financial performance or strategic shifts.

Positives

• CEO granted significant stock options, aligning executive interests with shareholder value.
• Stockholder approval obtained for the amended 2021 Stock Incentive Plan, indicating support for the company's incentive structures.
• Clear vesting schedule over three years promotes long-term commitment from leadership.

Negatives

• The grant is contingent on stockholder approval, which introduces a potential point of failure if approval were not obtained (though it was obtained).
• The exercise price of $3.14 per share suggests the stock price at the time of grant was at or above this level, but future appreciation is required for the options to be in-the-money.

Risks

• The effectiveness of the option grant was dependent on stockholder approval of the amended 2021 Stock Incentive Plan.
• Future stock price performance is critical for the value of these options to be realized by the CEO.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the CEO's continued service, as the options vest over three years and have an exercise price of $3.14.

Industry Context

StockSavvy.ai notes that the granting of stock options to key executives, particularly the CEO, is a common practice in the biotechnology sector to incentivize performance and align leadership with shareholder interests, especially during periods of development and potential growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns CEO incentives with potential stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: The approval of the stock incentive plan may pave the way for other equity-based compensation, potentially motivating other employees.
• Management: The CEO receives a direct financial incentive tied to the company's success.

Next Steps

• The stock options will vest according to the schedule outlined, starting one year from May 28, 2026.
• The CEO may exercise the vested options at the price of $3.14 per share, subject to market conditions and company performance.

Key Dates

Keywords

Cellectar Biosciences, CLRB, Form 4, Stock Options, Executive Compensation, James V. Caruso, Insider Trading, SEC Filing, Stock Incentive Plan